ADGRE2 : A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 09.11.2026. Verfasst von Jennifer Neiss und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Receptors, G-Protein-Coupled. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leukämiehilfe Steiermark, Austrian Science Fund.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) are heterogeneous myeloid malignancies with limited therapeutic options and often poor long‐term prognosis due to persistence of therapy‐resistant leukemic stem cells (LSC). Immunotherapeutic approaches have demonstrated high efficacy in lymphoid malignancies, but their application in AML and CMML remains challenging due to the lack of targetable (neo‐)antigens. Here we investigated the expression of the adhesion G protein‐coupled receptor E2 (ADGRE2) in diagnostic samples from 124 AML and 28 CMML patients using multiparameter flow cytometry and publicly available expression databases. ADGRE2 was significantly overexpressed on leukemic blasts in both AML and CMML compared to normal CD34 + hematopoietic stem and progenitor cells (HSPCs). ADGRE2 surface expression was high within the CD34 + /38 − and GPR56 high LSC‐enriched compartments, comparably distributed with minor differences among subgroups and high in distinct samples with low expression of established immunotherapeutic targets, such as CD33 and CLL‐1. Our findings further corroborate ADGRE2 as a promising (complementary) immunotherapeutic target in myeloid malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Medical University of Graz, Graz, Austria.
- Otto-Loewi-Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, Graz, Austria.
- Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
ORCID-Profile: Jennifer Neiss, Marc Rijksen, Armin Zebisch, Andreas Reinisch, Heinz Sill, Annkristin Heine, Albert Wölfler
Förderung
- Leukämiehilfe Steiermark
- Austrian Science Fund
Zitieren
APA
Neiss, J., Hemetsberger, L., Schaefer, C., Rijksen, M., Schwab, A., Zebisch, A., Reinisch, A., Sill, H., Heine, A., & Wölfler, A. (2026). ADGRE2 : A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72497
Vancouver
Neiss J, Hemetsberger L, Schaefer C, Rijksen M, Schwab A, Zebisch A, et al. ADGRE2 : A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72497
BibTeX
@article{Neiss2026,
author = {Neiss, Jennifer and Hemetsberger, Lisa and Schaefer, Carolin and Rijksen, Marc and Schwab, Antonia and Zebisch, Armin and Reinisch, Andreas and Sill, Heinz and Heine, Annkristin and Wölfler, Albert},
title = {ADGRE2 : A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72497}
}
EUVIMED